ClinicalTrials.Veeva

Menu

Knotless Implants As an Alternative for Capsular Closure in Primary Hip Arthroscopy: a Prospective, Multi-Center Study

A

American Hip Institute

Status and phase

Enrolling
Phase 4

Conditions

Femoro Acetabular Impingement

Treatments

Device: Control Arm
Device: LoopLoc Arm

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT06500364
IIRR-01891

Details and patient eligibility

About

The purpose of this research is to see if the Arthrex LoopLocTM device is better for capsular closure during hip arthroscopy than other treatments available.

The hip capsule is the tissue that surrounds your hip joint. It stabilizes and supports your hip joint. During hip arthroscopy, this tissue must be cut through in order to perform the hip arthroscopy. Once the hip arthroscopy is completed, the surgeon might repair the capsule. Current ways of repairing the capsule include knotted suture that might irritate structures around the hip, leading to the possible formation of scar tissue and pain. The Arthrex LoopLocTM device is knotless and may lower the presence of irritation and scar tissue around the hip after surgery and might lead to better outcomes.

Therefore, researchers will compare patients who had the LoopLocTM device used to close their hip capsule during surgery to those who did not have the device used, to see if there is a difference in their outcomes following surgery.

Full description

The purpose of the study is to perform a prospective multi-center study evaluating the feasibility of a knotless capsular closure device in patients undergoing primary hip arthroscopy.

All patients that meet study inclusion and exclusion criteria will then be informed about the study and given the IRB-approved consent form. All patients will learn about the study during a clinic visit and will have the opportunity to review the consent form and ask questions. All questions and concerns about study participation and the consent form will be addressed by staff and staff will ensure patient understanding of the consent form. The study participant will then sign and date the consent form, as well as the research staff obtaining consent. Consent can be withdrawn at any time the participant chooses either verbally or in writing.

Patients will be indicated by their physician for a capsular closuring using the LoopLocTM device. These patients will follow up for two years with their providers and researchers, who will collect their patient-reported and clinical outcomes. Data from this study will be analyzed to determine if the LoopLocTM device for capsular closure has better outcomes than the alternative treatments available.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients undergoing a primary hip arthroscopy
  • Patients younger than 60 years old.
  • Patients who will receive capsular closure with the Arthrex LoopLocTM device following hip arthroscopy.

Exclusion criteria

  • Patients that had previous hip surgery,
  • Patients that had a center edge angle (CEA) less than 25 degrees or greater than 40 degrees.
  • Patients that have a cartilage damage grade greater than or equal to 3.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

80 participants in 2 patient groups

LoopLoc Arm
Experimental group
Description:
The patients in this group will have the LoopLoc device used following their hip arthroscopy, to close the capsule.
Treatment:
Device: LoopLoc Arm
Control Arm
Active Comparator group
Description:
This is a control group, meaning they had their hip arthroscopy done without the use of the LoopLoc device.
Treatment:
Device: Control Arm

Trial contacts and locations

1

Loading...

Central trial contact

Benjamin Domb; Alexandra Mantice

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems